KOSDAQBiotech & Pharma338840

Y-Biologics

₩7,740▼ 0.77%2026-11-18 close
Market Cap
₩119.2B
Turnover
₩200M
Volume
30K
Shares out.
15.4M
PER
—
PBR
11.0×
EPS
-₩3,529
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Preclinical Multi-AbKine data amid continued losses

Y-Biologics is seeking licensing deals for its preclinical multispecific immuno-oncology pipeline, while operating losses have continued for four straight fiscal years and across the last five quarters.

  1. 1

    On a DART-filed basis, revenue peaked at KRW 5.76 billion in 2024 and fell to KRW 2.91 billion in 2025.

  2. 2

    The 2025 net loss attributable to controlling shareholders widened to KRW 42 billion from KRW 6.44 billion in 2024, and KRW 35.1 billion of it fell in the fourth quarter.

  3. 3

    The core assets AR170 and AR166 are both at the preclinical stage, with an IND filing targeted for 2027.

  4. 4

    After the KRW 35 billion convertible bond decision in 2025, the debt-to-equity ratio rose to 109.8%.

  5. 5

    PER cannot be calculated because the last four quarters were net losses, and no dividend is being paid.

02

Business structure

Y-Biologics was founded in 2007 as an antibody drug developer and listed on KOSDAQ in December 2023 through the technology special listing route. Its discovery platform, Ymax-ABL, underpins joint research and licensing agreements with drug developers in Korea and abroad.

The business flows from platform provision to licensing and then co-development, and revenue comes mainly from technology fees paid by partners and from contract research.

The 2024 revenue of KRW 5.76 billion reflected a partner's August 2024 licensing deal with a Chinese drug company, under which Y-Biologics received a share of the technology fees, and press reports described it as the largest since 2020.

Its own pipeline centers on AR170 (PD-1×VEGF×IL-2v) and AR166 (PD-1×LAG-3×IL-2v), derived from the Multi-AbKine multispecific antibody-cytokine fusion platform, and both are preclinical.

Earlier, the PD-1 monoclonal antibody arklicesmab (YBL-006) was out-licensed, and reports described it as the first domestic antibody of its kind to enter clinical development. Co-development pipelines are reported at more than ten, with LigaChem Biosciences among the partners cited.

Its customers are global big pharma and biotech companies, and the company announced participation in BIO USA in June 2026 and BIO-Europe 2026 in November 2026.

In competition, the single-target PD-1 segment is already occupied by blockbusters such as Keytruda and Opdivo, so the company positions its multi-target and cytokine-fusion approach as differentiation. Revenue tends to move sharply with the timing of technology fee recognition.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩2.5B−283.5%
2025Q4₩400M-₩3B−665.5%
2026Q1₩300M-₩3.9B−1376.4%
2026Q2₩1.5B-₩3.8B−244.9%
2026Q3₩300M-₩5.1B−1739.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩4.2B-₩18.8B-₩18.8B−453.7%−153.0%138.5%
2023₩3.5B-₩10.1B-₩20.9B−291.5%−89.2%29.4%
2024₩5.8B-₩8.4B-₩6.4B−146.6%−35.1%18.4%
2025₩2.9B-₩9.3B-₩42B−318.2%−158.0%109.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-filed basis, annual revenue was KRW 4.15 billion in 2022, KRW 3.48 billion in 2023 (down 16.2% year on year), KRW 5.76 billion in 2024 (up 65.6%), and KRW 2.91 billion in 2025 (down 49.5%). Among 2022 to 2025, 2024 was the largest year and 2025 the smallest.

The 2024 increase was reported to reflect technology fees shared from a partner's licensing deal, and in 2025 revenue fell as that fee income dropped out.

Operating losses narrowed from KRW 18.8 billion in 2022 to KRW 10.1 billion in 2023 and KRW 8.45 billion in 2024, then widened to KRW 9.27 billion in 2025, so the company has recorded losses in each of the four years from 2022 to 2025.

The operating margin improved from -453.7% in 2022 to -146.6% in 2024 but deteriorated to -318.2% in 2025.

Net losses attributable to controlling shareholders were KRW 18.8 billion in 2022, KRW 20.9 billion in 2023, KRW 6.44 billion in 2024, and KRW 42 billion in 2025, and KRW 35.1 billion of the 2025 total came in the fourth quarter.

Fourth-quarter operating loss was KRW 2.99 billion, so the gap between operating and net losses is large, and the sources of non-operating or one-off items should be checked in the annual report. Net loss including non-controlling interests matched the controlling-shareholder figure in each year.

Quarterly revenue went from KRW 892 million in the third quarter of 2025 to KRW 449 million in the fourth quarter and KRW 282 million in the first quarter of 2026, jumped to KRW 1.55 billion in the second quarter, and then fell 81.2% to KRW 292 million in the third quarter, down 67.3% from a year earlier.

Quarterly operating losses ran from KRW 2.53 billion in the third quarter of 2025 to KRW 5.07 billion in the third quarter of 2026, five straight loss quarters, and the controlling-shareholder net loss over the last four quarters totals KRW 53 billion.

Operating cash flow was negative KRW 10.1 billion in 2022, narrowed to negative KRW 4.14 billion in 2024, then widened to negative KRW 5.84 billion in 2025. The debt-to-equity ratio rose to 109.8% at the end of 2025 from 18.4% in 2024, with total liabilities of KRW 29.2 billion against total equity of KRW 26.6 billion.

05

Industry analysis

The focus of immuno-oncology development is moving from single-target PD-1 agents toward multispecific antibodies that engage several targets at once. The company says global cancer drug research is shifting toward multispecific approaches that fit its platform.

Grow Research noted that in a market where large PD-1×VEGF deals keep appearing, pipelines with differentiated preclinical data are likely to draw attention from big pharma.

Drug developers are also moving to secure preclinical multispecific technology early to strengthen their next-generation immuno-oncology portfolios.

IL-2-based therapies have long faced concerns about systemic toxicity, and the company is pursuing IL-2 variant (IL-2v) designs meant to reduce that burden while raising efficacy.

Reports on AACR 2026 preclinical data said AR170 showed stronger antitumor effects than the reference agent ivonescimab, but this is a preclinical comparison only. On positioning, the company highlights that it holds platforms across generations, from discovery to bispecific and multifunctional antibodies.

An industry source described few domestic companies as having systematic platforms across all these generations. Direct comparison with competing drugs remains at the preclinical level, so how persuasively the company can show patient applicability is the key question.

06

Outlook

The company said in a 2025 interview that it expects large licensing outcomes to become visible in 2026 and 2027.

Reports say a KRW 35 billion convertible bond issued in July 2025, combined with government-supported projects, secured research funding of KRW 50 billion in total, and the company said it plans to put KRW 15 billion into AR170 and KRW 9.5 billion into AR166 for clinical development.

Its 2026 conference activity began with AACR 2026 in April, where it presented preclinical data on AR170 and AR166 and research on IL-2v screening.

For SITC 2026, held November 4 to 8, the company announced two poster presentations covering expanded preclinical data and ex vivo translational results using patient-derived tissue.

It then said it would hold partnering meetings with global drug developers at BIO-Europe 2026 on November 9 to 11, using materials that include primate toxicity study data.

Grow Research expects that completing the remaining tasks, including the 2027 IND filing and GLP toxicology studies, on schedule could be the trigger for a re-rating. In May 2026 the company also said it would supplement its data on mechanisms of action in cancer patient tissue.

The next checkpoints are whether the IND is filed in 2027 and the terms and timing of any large licensing agreement.

07

Valuation

PER
—
PBR
11.0×
ROE
-414.1%
EPS
-₩3,529
BPS
₩796
Dividend per share
₩0

Because the last four quarters were net losses, PER cannot be calculated, so comparison against earnings does not work. On an asset basis, the price-to-book ratio sits in a range with a large premium over net asset value, which can be read as the market pricing pipeline licensing potential well above book assets.

Total equity of KRW 26.6 billion at the end of 2025 is entirely attributable to controlling shareholders, while total liabilities of KRW 29.2 billion exceed equity. No dividend is paid, so the dividend yield sits below the sector average.

Over several years, losses narrowed in 2024 and widened again in 2025, so it is too early to describe this as an earnings recovery. Because earnings-based metrics are limited, market value appears to form between pipeline expectations and cash needs.

Comparison with listed peers is also narrow on earnings metrics, which makes the outcome of any licensing deal a major variable in valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Differentiated preclinical data

The company presented preclinical data on AR170 and AR166 at AACR 2026 in April 2026. The independent research firm Grow Research summarized AR170 survival of 70% against a competitor and complete response of AR166 in a resistant tumor model.

The firm viewed the easing of systemic toxicity concerns for IL-2 therapies as a strong basis for future licensing talks.

Wider partnering activity

The company announced participation in BIO USA in June 2026 and in BIO-Europe 2026 in November 2026. A company official said more big pharma companies are showing interest in the Multi-AbKine platform. The global push to secure multispecific technology at the preclinical stage provides the backdrop for these talks.

2027 IND target and funding

Grow Research considered that carrying out the 2027 IND filing and GLP toxicology studies as planned could trigger a re-rating of the pipeline. The KRW 35 billion convertible bond of 2025 is cited as funding for clinical development of AR170 and AR166.

09

Bear factors

Thin revenue base

On a DART-filed basis, 2025 revenue of KRW 2.91 billion fell 49.5% from the prior year. Quarterly revenue in 2026 was KRW 282 million in the first quarter, KRW 1.55 billion in the second, and KRW 292 million in the third, a wide swing. The fact that results still swing with the timing of fee income is a weakness.

Persistent losses and wider net loss

The 2025 operating loss was KRW 9.27 billion, and the third-quarter 2026 operating loss was KRW 5.07 billion, marking five straight loss quarters. The controlling-shareholder net loss over the last four quarters totals KRW 53 billion, including KRW 35.1 billion in the fourth quarter of 2025. The difficulty of building a valuation case on earnings metrics is a burden.

Higher debt and cash outflow

The debt-to-equity ratio rose to 109.8% at the end of 2025 from 18.4% in 2024. Total liabilities of KRW 29.2 billion exceed total equity of KRW 26.6 billion. Operating cash flow was negative KRW 5.84 billion in 2025, a larger outflow than the negative KRW 4.14 billion in 2024.

10

Risk factors

Delay in clinical entry

The core assets AR170 and AR166 are both preclinical, with a 2027 IND filing as the target. Remaining IND-enabling work, including GLP toxicology studies, means any schedule slip could affect licensing talks and valuation. Patient applicability is being supported through conference data, but clinical data have not yet proven it.

Timing of licensing and earnings swings

Large licensing deals the company expects will not show up in results until the timing and terms are disclosed. Revenue rose sharply in 2024 on shared partner fees and fell in 2025, so the timing of revenue recognition adds to earnings volatility. Whether the 2026 quarterly swings follow the same pattern should be examined in the annual report.

Funding needs and dilution

The KRW 35 billion convertible bond of 2025 is a funding tool for clinical work, but conversion would increase shares outstanding and dilute per-share value. Reports put cash and equivalents at about KRW 12 billion at the end of 2024, and operating cash outflow was KRW 5.84 billion in 2025. The continuing need for additional funding is a risk.

11

What to watch next

  1. Late March 2027 (statutory annual report deadline)

    The 2026 annual report will show full-year revenue and operating loss, the non-operating items behind the gap between the KRW 35.1 billion fourth-quarter net loss and the operating loss, and the composition of fee income.

  2. 2026–2027 (company's expected window)

    Whether a large licensing agreement is disclosed, and its terms such as upfront payments, is the biggest variable for fee income and cash flow.

  3. 2027

    This is the target year for IND filings of AR170 and AR166, and a filing would be the first formal sign of these assets moving into clinical development.

  4. Mid-May 2027 (Q1 quarterly report statutory deadline)

    First-quarter 2027 revenue and operating loss will show whether losses stay near the KRW 5.07 billion level of the third quarter of 2026.

12

Overall view

Y-Biologics is trying to shift from a licensing-led model toward a model centered on its own pipeline, built on its multispecific immuno-oncology platform.

Its DART-filed results show losses in each year from 2022 to 2025, and apart from 2024, when fee income lifted revenue to KRW 5.76 billion, the revenue base has been thin.

In 2025 revenue fell to KRW 2.91 billion and the net loss attributable to controlling shareholders widened to KRW 42 billion, and losses have continued for five straight quarters from the third quarter of 2025 through the third quarter of 2026.

Strengths include the preclinical data on AR170 and AR166, the Multi-AbKine platform, and partnering activity at BIO USA and BIO-Europe. Weaknesses include core assets still at the preclinical stage, and a debt-to-equity ratio that rose to 109.8% in 2025, increasing funding pressure.

The strength of the preclinical data is viewed differently by different observers, and whether deals are signed remains the key variable. The next checkpoints are the operating margin and cash flow in the 2026 annual report, whether the 2027 IND is filed, and the terms and timing of any large licensing disclosure.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. view.asiae.co.kr
  2. view.asiae.co.kr
  3. hankyung.com
  4. daily.hankooki.com
  5. newspim.com
  6. markets.hankyung.com
  7. newspim.com
  8. m.news.nate.com
  9. newspim.com
  10. newspim.com
  11. files-scs.pstatic.net
  12. theinvest.co.kr
  13. calculator.io.kr
  14. sisajournal-e.com
  15. m.thinkpool.com
  16. pharm.edaily.co.kr
  17. businesspost.co.kr
  18. ybiologics.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis